Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NOTA-Evans Blue
- Development stage
- Phase 1
- Lead developer
- National Institute of Biomedical Imaging and Bioengineering
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous (for Certain Pet/ct Protocols)[4][7]
01
Overview
**68Ga-NOTA-Evans Blue** is a diagnostic radiopharmaceutical agent used primarily for positron emission tomography/computed tomography (PET/CT) imaging of the lymphatic system. It consists of Evans blue dye conjugated to the chelator NOTA, which is then labeled with the radioisotope gallium-68. After administration, it binds to serum albumin in vivo, forming a complex that remains largely within the blood pool and lymphatic vessels. This property enables high-quality imaging of blood and lymphatic circulation and related disorders. The agent has been investigated for its ability to diagnose and evaluate various lymphatic disorders such as lymphedema, lymphangioma, and particularly for differentiating hepatic hemangiomas from other liver lesions. Its mechanism relies on albumin binding by Evans blue, facilitating visualization of vascular or lymphatic abnormalities via PET/CT[1][4][6]. The drug was developed by researchers at the National Institute For Biomedical Imaging And Bioengineering (NIBIB), with clinical studies also involving Peking Union Medical College Hospital[1].
- Other names
- 68Ga-NOTA Evans BlueGallium-68 NOTA Evans BlueGallium68 NOTA Evans BlueGallium 68 NOTA Evans Blue
Beyond the preview
Go deeper on 68Ga-NOTA-Evans Blue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NOTA-Evans Blue.